Silver Diamine Fluoride Stops Pediatric Tooth Decay Without Drilling
A major Phase III clinical trial published in JAMA Pediatrics confirms that a 38% silver diamine fluoride liquid can successfully arrest tooth decay in more than half of affected baby teeth in young children without requiring drilling, injections, or sedation.
In Plain English: The Clinical Takeaway
- Mechanism of Action: Silver diamine fluoride (SDF) combines silver, which combats bacteria associated with tooth decay, with fluoride, which helps strengthen the mineral structure of teeth and resist further damage.
- Application Method: A dentist uses a tiny sponge tipped applicator to paint the liquid directly onto the cavity in a matter of seconds.
Clinical Trial Results and Pediatric Dental Pain
Tooth decay is the most common chronic disease among children, affecting more than 40% of American children. For young children, conventional dental treatment can be particularly challenging. Some are too young to remain still throughout a procedure, while others experience significant fear or anxiety. In more extreme cases, children require dental surgery under general anesthesia, which makes them completely unconscious during the procedure.
A simple, inexpensive liquid called silver diamine fluoride, or SDF, could spare many of those children. Applied to a cavity with a tiny sponge-tipped applicator in about a few second’s time per tooth, SDF arrests decay without drilling, shots or sedation.
To evaluate a less invasive intervention, researchers led by the University of Michigan conducted a Phase III clinical trial involving 830 children younger than 6. The investigation began in 2018 and continued despite the major disruptions caused by the COVID-19 pandemic.
The trial evaluated Advantage Arrest 38% SDF, supplied by Elevate Oral Care. When provided at six-month intervals, the solution successfully stopped decay in more than half of the affected baby teeth. Unlike a traditional filling, the treatment does not replace lost tooth structure. Instead, it helps prevent existing decay from progressing.
| Trial Parameter | Clinical Detail |
|---|---|
| Study Design | Phase III Clinical Trial |
| Participant Demographics | 830 children younger than 6 |
| Intervention Agent | 38% Silver Diamine Fluoride (Advantage Arrest) |
| Application Frequency | Six month intervals |
| Efficacy Rate | Successfully stopped decay in more than half of affected baby teeth |
| Primary Funding Source | National Institute of Dental and Craniofacial Research (more than $12 million) |
Regulatory History and Off-Label Utilization
According to Amr Moursi, a professor of pediatric dentistry at New York University College of Dentistry and a co-principal investigator on the study, the results support FDA approval of SDF for managing arrest of tooth decay in young children. Removing SDF from off-label status could lead to increased utilization by providers, enhanced payments by insurers and more consistent product quality.
Expanding Access Through Medical and Dental Integration
Every year, thousands of young children in the United States visit emergency departments because of untreated cavities.
References
- JAMA Pediatrics: Phase III Clinical Trial of Silver Diamine Fluoride in Young Children.
- U.S. Food and Drug Administration (FDA): Medical Device Approval for Tooth Sensitivity (2014).
- National Institute of Dental and Craniofacial Research (NIDCR): Research Project Grant Funding ($12M+).
- University of Michigan School of Dentistry: Clinical Investigation Reports.
